tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
APR-1051’s Emerging Best-in-Class WEE1 Profile Underpins Buy Rating on Aprea Therapeutics
PremiumRatingsAPR-1051’s Emerging Best-in-Class WEE1 Profile Underpins Buy Rating on Aprea Therapeutics
12d ago
Aprea Therapeutics price target lowered to $7 from $11 at Wedbush
Premium
The Fly
Aprea Therapeutics price target lowered to $7 from $11 at Wedbush
12d ago
Aprea Therapeutics appoints Kennedy as Chief Medical Advisor
Premium
The Fly
Aprea Therapeutics appoints Kennedy as Chief Medical Advisor
18d ago
Aprea Therapeutics Updates Oncology Pipeline and Strategy Outlook
PremiumCompany AnnouncementsAprea Therapeutics Updates Oncology Pipeline and Strategy Outlook
1M ago
Aprea Therapeutics files to sell 5.5M shares of common stock for holders
Premium
The Fly
Aprea Therapeutics files to sell 5.5M shares of common stock for holders
2M ago
Advancing APR-1051 in HPV-Positive Cancers and Extended Cash Runway Underpin Aprea Therapeutics Buy Rating and $5 Target
Premium
Ratings
Advancing APR-1051 in HPV-Positive Cancers and Extended Cash Runway Underpin Aprea Therapeutics Buy Rating and $5 Target
2M ago
Aprea Therapeutics: Promising Advancements in Synthetic Lethality Programs Drive Buy Rating
PremiumRatingsAprea Therapeutics: Promising Advancements in Synthetic Lethality Programs Drive Buy Rating
3M ago
Aprea Therapeutics Reports Ongoing Financial Challenges
Premium
Company Announcements
Aprea Therapeutics Reports Ongoing Financial Challenges
3M ago
Aprea Therapeutics Reports Q3 Results and Clinical Updates
Premium
Company Announcements
Aprea Therapeutics Reports Q3 Results and Clinical Updates
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100